Total Price: $0.00
Contact Information
Recombinant Human Galectin-3/LGALS3 Protein (His Tag)(Active)
SKU: PKSH032473-50
Recombinant Human Galectin-3/LGALS3 Protein (His Tag)(Active)
| SKU # | PKSH032473 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | 35 kDa Lectin, CBP35, Carbohydrate-Binding Protein 35, GAL3, GALBP, GALIG, Gal-3, Galactose-Specific Lectin 3, Galactoside-Binding Protein, Galectin-3, IgE-Binding Protein, L-31, L31, LGALS2, LGALS3, Laminin-Binding Protein, Lectin L-29, MAC2, Mac-2 Antigen, P35 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Ala2-Ile250 |
| Accession | AAH53667.1 |
| Calculated Molecular Weight | 27.2 kDa |
| Observed Molecular Weight | 35 kDa |
| Tag | C-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution of PBS, 3mM DTT, pH 7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Galectin-3(LGALS3) is also known as Galactose-specific lectin 3; Mac-2 antigen; Carbohydrate-binding protein 35; Laminin-binding protein and Galactoside-binding protein. LGALS3 is highly expressed in early stages of papillary carcinoma; and lowly during tumor progression. LGALS3 is probably forms homo- or heterodimers and secreted by a non-classical secretory pathway and associates with the cell surface. LGALS3 plays an important role during the acquisition of vasculogenic mimicry and angiogenic properties. LGLAS3 takes part in an immune regulator to inhibit T-cell immune responses and promote tumor growth; as a result providing a new mechanism for tumor immune tolerance.